Form 4: Supernus Pharmaceuticals Director Newhall Reports Stock Unit Settlement
SEC Form 4 Filing
Director Charles W. Newhall III reports the settlement of restricted stock units into Supernus Pharmaceuticals common stock.
Summary
- On February 22, 2025, Charles W. Newhall III, a director of Supernus Pharmaceuticals, Inc., had 5,369 restricted stock units settled into common stock.
- The transaction resulted in Newhall acquiring 5,369 shares of common stock at a price of $0 per share.
- Following the transaction, Newhall directly owns 135,644 shares of Supernus Pharmaceuticals common stock.
- The restricted stock units vested and were settled on the same date.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a routine transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions, providing transparency to investors regarding the holdings and transactions of company directors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 02/22/2025 | Date of transaction: settlement of restricted stock units and acquisition of common stock. |
| 02/24/2025 | Date of signature on the Form 4 filing. |
Keywords
Supernus Pharmaceuticals, Director, Stock Units, Beneficial Ownership, Form 4, Newhall, SUPN, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.